title: Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?
authors.affiliation: Cellular and Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia. mark.febbraio@bakeridi.edu.au
authors.forename: M A
authors.initials: MA
authors.lastname: Febbraio
authors.forename: S
authors.initials: S
authors.lastname: Rose-John
authors.forename: B K
authors.initials: BK
authors.lastname: Pedersen
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000503:physiopathology; D016503:Drug Delivery Systems; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D007249:Inflammation / Q000188:drug therapy* / Q000503:physiopathology; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019947:Receptors, Interleukin-6; C502936:tocilizumab